Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pioglitazone and Risk of Bladder Cancer in Patients With Type 2 Diabetes Mellitus"PROBE-PIO"Study

NCT01935466 is registered in ClinicalTrials.gov with Post Graduate Institute of Medical Education and Research, Chandigarh as lead sponsor.

NCT NCT01935466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01935466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pioglitazone and Risk of Bladder Cancer in Patients With Type 2 Diabetes Mellitus"PROBE-PIO"Study
Lead sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase
Observational
Overall status
Completed
Start date
July 31, 2013
Completion date
October 31, 2021
Enrollment
6,107 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer